To include your compound in the COVID-19 Resource Center, submit it here.

Aromasin exemestane: Phase III data

The double-blind, international Phase III MAP.3 trial in 4,560 postmenopausal women who were at a moderately increased risk for breast cancer showed that Aromasin met

Read the full 258 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE